Paratek Pharmaceuticals Overview
Latest ROE for Paratek Pharmaceuticals: 31.15% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow31.15%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Paratek Pharmaceuticals posts a ROE of 31.15%. That is above the Healthcare sector average of -75.59%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near -75.59% is typical. Paratek Pharmaceuticals's 31.15% is higher that level. That is roughly 141.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Paratek Pharmaceuticals's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 31.15%; use YoY and peer views to separate noise from signal.
Context for PRTK's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -75.59%), and (3) consistency with growth and profitability. This page covers the first two; Paratek Pharmaceuticals's other metric pages and overview cover the third.
Judging Paratek Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 31.15% here, then scan peer and history charts to see if the gap is persistent.
